NCT01136876COMPLETEDanonymous

Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin as New Biomarker in Patients With Moderate Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320

Sponsor

Source record

Bracco Diagnostics, Inc

Phase

Source record

PHASE4

Modality

AI-normalized

small molecule

Target

AI-normalized

Iopamidol, Iodixanol-320

Indication / condition

AI-normalized

Coronary Artery Stenosis

Intervention

Source record

Iopamidol, Iodixanol-320

Related intelligence directories

Indication directory: Coronary Artery Stenosis Modality directory: small molecule Target directory: Iopamidol

Source & freshness

Source record

NCT ID

NCT01136876

Original source

ClinicalTrials.gov

Source last updated

Nov 04, 2020

Ingested at

Jun 05, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01136876

Title

Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin as New Biomarker in Patients With Moderate Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320

Sponsor

Bracco Diagnostics, Inc

Status

COMPLETED

Phase

PHASE4

Condition raw

Coronary Artery Stenosis

Condition normalized

Coronary Artery Stenosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Iopamidol, Iodixanol-320

Target normalized

Iopamidol, Iodixanol-320

Interventions

Iopamidol, Iodixanol-320

Public preview

Source record

To compare Iopamidol injection 370 and Iodixanol 320 in evaluating Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with moderate fall in eGFR

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin as New Biomarker in Patients With Moderate Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT01136876

Status

COMPLETED

Phase

PHASE4

Sponsor

Bracco Diagnostics, Inc

Executive brief

Investment-Ready Snapshot

To compare Iopamidol injection 370 and Iodixanol 320 in evaluating Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with moderate fall in eGFR

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedNov 04, 2020

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01136876

Indication

Coronary Artery Stenosis

Modality

small molecule

Target

Iopamidol, Iodixanol-320

Intervention

Iopamidol, Iodixanol-320

Source record